Intrahepatic transcriptomics reveals gene signatures in chronic hepatitis B patients responded to interferon therapy

References

• Revill PA, Chisari FV, Block JM, et al. A global scientific strategy to cure hepatitis B. Lancet Gastroenterol Hepatol. 2019;4:545–558.
   PubMed Web of Science ®Google Scholar
• Zoulim F, Lebosse F, Levrero M. Current treatments for chronic hepatitis B virus infections. Curr Opin Virol. 2016;18:109–116.
   PubMed Web of Science ®Google Scholar
• Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet. 2005;365:123–129.
   PubMed Web of Science ®Google Scholar
• Chisari FV, Isogawa M, Wieland SF. Pathogenesis of hepatitis B virus infection. Pathol Biol (Paris). 2010;58:258–266.
   PubMed Web of Science ®Google Scholar
• Fanning GC, Zoulim F, Hou J, et al. Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat Rev Drug Discov. 2019;18:827–844.
   PubMed Web of Science ®Google Scholar
• Sarasin-Filipowicz M, Oakeley EJ, Duong FH, et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci USA. 2008;105:7034–7039.
   PubMed Web of Science ®Google Scholar
• Xiao C, Qin B, Chen L, et al. Preactivation of the interferon signalling in liver is correlated with nonresponse to interferon alpha therapy in patients chronically infected with hepatitis B virus. J Viral Hepat. 2012;19:e1–e10.
   PubMed Web of Science ®Google Scholar
• Allweiss L, Volz T, Lutgehetmann M, et al. Immune cell responses are not required to induce substantial hepatitis B virus antigen decline during pegylated interferon-alpha administration. J Hepatol. 2014;60:500–507.
   PubMed Web of Science ®Google Scholar
• Fletcher SP, Chin DJ, Gruenbaum L, et al. Intrahepatic transcriptional signature associated with response to interferon-alpha treatment in the woodchuck model of chronic hepatitis B. PLoS Pathog. 2015;11:e1005103.
   PubMed Web of Science ®Google Scholar
• Micco L, Peppa D, Loggi E, et al. Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. J Hepatol. 2013;58:225–233.
   PubMed Web of Science ®Google Scholar
• Wu HL, Hsiao TH, Chen PJ, et al. Liver gene expression profiles correlate with virus infection and response to interferon therapy in chronic hepatitis B patients. Sci Rep. 2016;6:31349.
   PubMed Web of Science ®Google Scholar
• Jansen L, de Niet A, Makowska Z, et al. An intrahepatic transcriptional signature of enhanced immune activity predicts response to peginterferon in chronic hepatitis B. Liver Int. 2015;35:1824–1832.
   PubMed Web of Science ®Google Scholar
• Gill US, Pallett LJ, Thomas N, et al. Fine needle aspirates comprehensively sample intrahepatic immunity. Gut. 2019;68:1493–1503.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. Electronic address EEE, European Association for the study of the L. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370–398.
   PubMed Web of Science ®Google Scholar
• Vanpouille-Box C, Hoffmann JA, Galluzzi L. Pharmacological modulation of nucleic acid sensors – therapeutic potential and persisting obstacles. Nat Rev Drug Discov. 2019;18:845–867.
   PubMed Web of Science ®Google Scholar
• Schoggins JW, Wilson SJ, Panis M, et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature. 2011;472:481–485.
   PubMed Web of Science ®Google Scholar
• Sadler AJ, Williams BR. Interferon-inducible antiviral effectors. Nat Rev Immunol. 2008;8:559–568.
   PubMed Web of Science ®Google Scholar
• Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol. 2014;32:513–545.
   PubMed Web of Science ®Google Scholar
• Iannacone M, Guidotti LG. Immunobiology and pathogenesis of hepatitis B virus infection. Nat Rev Immunol. 2022;22:19–32.
   PubMed Web of Science ®Google Scholar
• Seeger C, Mason WS. Molecular biology of hepatitis B virus infection. Virology. 2015;479–480:672–686.
   PubMed Web of Science ®Google Scholar
• Heijtink RA, Janssen HL, Hop WC, et al. Interferon-alpha therapy for chronic hepatitis B: early response related to pre-treatment changes in viral replication. J Med Virol. 2001;63:217–219.
   PubMed Web of Science ®Google Scholar
• Kako M, Kanai K, Aikawa T, et al. Response to interferon-alpha 2a in patients with e antigen-negative chronic hepatitis B. J Clin Gastroenterol. 1997;25:440–445.
   PubMed Web of Science ®Google Scholar
• Mitra B, Wang J, Kim ES, et al. Hepatitis B virus precore protein p22 inhibits alpha interferon signaling by blocking STAT nuclear translocation. J Virol. 2019;93:e00196.
   PubMed Web of Science ®Google Scholar
• Caselmann WH, Meyer M, Scholz S, et al. Type I interferons inhibit hepatitis B virus replication and induce hepatocellular gene expression in cultured liver cells. J Infect Dis. 1992;166:966–971.
   PubMed Web of Science ®Google Scholar
• Bonvin M, Achermann F, Greeve I, et al. Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication. Hepatology. 2006;43:1364–1374.
   PubMed Web of Science ®Google Scholar
• Tur-Kaspa R, Teicher L, Laub O, et al. Alpha interferon suppresses hepatitis B virus enhancer activity and reduces viral gene transcription. J Virol. 1990;64:1821–1824.
   PubMed Web of Science ®Google Scholar
• Wieland SF, Guidotti LG, Chisari FV. Intrahepatic induction of alpha/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice. J Virol. 2000;74:4165–4173.
   PubMed Web of Science ®Google Scholar
• Robek MD, Boyd BS, Wieland SF, et al. Signal transduction pathways that inhibit hepatitis B virus replication. Proc Natl Acad Sci U S A. 2004;101:1743–1747.
   PubMed Web of Science ®Google Scholar
• Wieland SF, Eustaquio A, Whitten-Bauer C, et al. Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids. Proc Natl Acad Sci USA. 2005;102:9913–9917.
   PubMed Web of Science ®Google Scholar
• Wieland SF, Chisari FV. Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol. 2005;79:9369–9380.
   PubMed Web of Science ®Google Scholar
• Xiong S, Zhu D, Liang B, et al. Longitudinal characterization of phenotypic profile of T cells in chronic hepatitis B identifies immune markers associated with HBsAg loss. EBioMedicine. 2021;69:103464.
   PubMed Web of Science ®Google Scholar
• Maini MK, Pallett LJ. Defective T-cell immunity in hepatitis B virus infection: why therapeutic vaccination needs a helping hand. Lancet Gastroenterol Hepatol. 2018;3:192–202.
   PubMed Web of Science ®Google Scholar
• Terawaki S, Chikuma S, Shibayama S, et al. IFN-alpha directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. J Immunol. 2011;186:2772–2779.
   PubMed Web of Science ®Google Scholar
• Sisirak V, Faget J, Gobert M, et al. Impaired IFN-alpha production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. Cancer Res. 2012;72:5188–5197.
   PubMed Web of Science ®Google Scholar
• Fisicaro P, Valdatta C, Massari M, et al. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology. 2010;138:682–693. 693 e1-4.
   PubMed Web of Science ®Google Scholar
• Li M, Sun R, Xu L, et al. Kupffer cells support hepatitis B virus-mediated CD8+ T cell exhaustion via hepatitis B core antigen-TLR2 interactions in mice. J Immunol. 2015;195:3100–3109.
   PubMed Web of Science ®Google Scholar
• Ma Z, Zhang E, Gao S, et al. Toward a Functional cure for hepatitis B: the rationale and challenges for therapeutic targeting of the B cell immune response. Front Immunol. 2019;10:2308.
   PubMed Web of Science ®Google Scholar
• Maini MK, Burton AR. Restoring, releasing or replacing adaptive immunity in chronic hepatitis B. Nat Rev Gastroenterol Hepatol. 2019;16:662–675.
   PubMed Web of Science ®Google Scholar
• Burton AR, Pallett LJ, McCoy LE, et al. Circulating and intrahepatic antiviral B cells are defective in hepatitis B. J Clin Invest. 2018;128:4588–4603.
   PubMed Web of Science ®Google Scholar
• Salimzadeh L, Le Bert N, Dutertre CA, et al. PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection. J Clin Invest. 2018;128:4573–4587.
   PubMed Web of Science ®Google Scholar
• Vanwolleghem T, Groothuismink ZMA, Kreefft K, et al. Hepatitis B core-specific memory B cell responses associate with clinical parameters in patients with chronic HBV. J Hepatol. 2020;73:52–61.
   PubMed Web of Science ®Google Scholar
• Schubert RD, Hu Y, Kumar G, et al. IFN-beta treatment requires B cells for efficacy in neuroautoimmunity. J Immunol. 2015;194:2110–2116.
   PubMed Web of Science ®Google Scholar
• van Buuren N, Ramirez R, Turner S, et al. Characterization of the liver immune microenvironment in liver biopsies from patients with chronic HBV infection. JHEP Rep. 2022;4:100388.
   PubMedGoogle Scholar
• Murray PJ. Macrophage polarization. Annu Rev Physiol. 2017;79:541–566.
   PubMed Web of Science ®Google Scholar
• Bility MT, Cheng L, Zhang Z, et al. Hepatitis B virus infection and immunopathogenesis in a humanized mouse model: induction of human-specific liver fibrosis and M2-like macrophages. PLoS Pathog. 2014;10:e1004032.
   PubMed Web of Science ®Google Scholar
• Li H, Zhai N, Wang Z, et al. Regulatory NK cells mediated between immunosuppressive monocytes and dysfunctional T cells in chronic HBV infection. Gut. 2018;67:2035–2044.
   PubMed Web of Science ®Google Scholar
• Fang Z, Li J, Yu X, et al. Polarization of monocytic myeloid-derived suppressor cells by hepatitis B surface antigen is mediated via ERK/IL-6/STAT3 signaling feedback and restrains the activation of T cells in chronic hepatitis B virus infection. J Immunol. 2015;195:4873–4883.
   PubMed Web of Science ®Google Scholar
• Yang F, Yu X, Zhou C, et al. Hepatitis B e antigen induces the expansion of monocytic myeloid-derived suppressor cells to dampen T-cell function in chronic hepatitis B virus infection. PLoS Pathog. 2019;15:e1007690.
   PubMed Web of Science ®Google Scholar
• Webb DS, Gerrard TL. IFN-alpha and IFN-gamma can affect both monocytes and tumor cells to modulate monocyte-mediated cytotoxicity. J Immunol. 1990;144:3643–3648.
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Shimabukuro-Demoto S, Tsutsui H, et al. Type I interferon limits mast cell-mediated anaphylaxis by controlling secretory granule homeostasis. PLoS Biol. 2019;17:e3000530.
   PubMed Web of Science ®Google Scholar
• Amiot L, Vu N, Rauch M, et al. Expression of HLA-G by mast cells is associated with hepatitis C virus-induced liver fibrosis. J Hepatol. 2014;60:245–252.
   PubMed Web of Science ®Google Scholar
• Amiot L, Vu N, Drenou B, et al. The anti-fibrotic role of mast cells in the liver is mediated by HLA-G and interaction with hepatic stellate cells. Cytokine. 2019;117:50–58.
   PubMed Web of Science ®Google Scholar
• Nirei K, Kanda T, Nakamura H, et al. Persistent hepatic inflammation plays a role in hepatocellular carcinoma after sustained virological response in patients with HCV infection. Int J Med Sci. 2018;15:466–474.
   PubMed Web of Science ®Google Scholar
• Madera S, Rapp M, Firth MA, et al. Type I IFN promotes NK cell expansion during viral infection by protecting NK cells against fratricide. J Exp Med. 2016;213:225–233.
   PubMed Web of Science ®Google Scholar
• Gill US, Peppa D, Micco L, et al. Interferon alpha induces sustained changes in NK cell responsiveness to hepatitis B viral load suppression In vivo. PLoS Pathog. 2016;12:e1005788.
   PubMed Web of Science ®Google Scholar
• Cervantes-Salazar M, Angel-Ambrocio AH, Soto-Acosta R, et al. Dengue virus NS1 protein interacts with the ribosomal protein RPL18: this interaction is required for viral translation and replication in Huh-7 cells. Virology. 2015;484:113–126.
   PubMed Web of Science ®Google Scholar
• Wei J, Kishton RJ, Angel M, et al. Ribosomal proteins regulate MHC class I peptide generation for immunosurveillance. Mol Cell. 2019;73:1162–1173 e5.
   PubMed Web of Science ®Google Scholar
• Huang JY, Su WC, Jeng KS, et al. Attenuation of 40S ribosomal subunit abundance differentially affects host and HCV translation and suppresses HCV replication. PLoS Pathog. 2012;8:e1002766.
   PubMed Web of Science ®Google Scholar
• Mitra B, Thapa RJ, Guo H, et al. Host functions used by hepatitis B virus to complete its life cycle: implications for developing host-targeting agents to treat chronic hepatitis B. Antiviral Res. 2018;158:185–198.
   PubMed Web of Science ®Google Scholar